Device Trial Radar · NCT07946718
Effects of Ozonated Oil Eye Drops on the Ocular Surface and Inflammation in Women
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Apr 1, 2025
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- University of SevilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Esteve Pharmaceuticals, S.A.
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study examines the effects of an eye gel containing liposomal ozonated oil in middle-aged women with dry eye disease. Dry eye can cause discomfort, an unstable tear film, and inflammation of the eye surface. The main questions are whether one week of treatment changes: Tear film stability and other signs and symptoms of dry eye. Markers of inflammation in cells collected from the eye surface. Proteins involved in maintaining connections between eye surface cells. Women with dry eye use the eye gel for one week and undergo assessments before and after treatment. These assessments include a symptom questionnaire, eye surface examinations, and collection of small samples of cells from the conjunctiva, the thin tissue covering the white of the eye. A separate group of healthy young women undergoes one assessment without receiving treatment. Their measurements provide reference values for comparison with those of women with dry eye.
Conditions
- Dry Eye Disease (DED)
Interventions
Liposomal Ozonated Oil Ophthalmic GelDevice
Topical ophthalmic administration of a sterile gel containing liposomal ozonated oil, hydroxyethylcellulose, and poloxamer 407 (OZONEST Gel-K). Participants instill one drop into each eye three times daily for seven consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in First Non-Invasive Tear Break-Up TimeTime frame: Baseline and Day 7
- Change From Baseline in Conjunctival IL1B mRNA ExpressionTime frame: Baseline and Day 7
- Change From Baseline in Conjunctival IL6 mRNA ExpressionTime frame: Baseline and Day 7
6 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Optometry and Contactology Clinic, Faculty of Pharmacy, University of Seville
Seville, Andalusia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.